Loading clinical trials...
Loading clinical trials...
Evaluation of EGFR and K-ras Mutations in Patients With Stage III NSCLC Treated on CALGB 30106
Conditions
Interventions
molecular diagnostic method
mutation analysis
Start Date
November 1, 2005
Primary Completion Date
March 1, 2006
Completion Date
July 1, 2010
Last Updated
June 29, 2016
NCT06066138
NCT06498635
NCT05198830
NCT07485114
NCT07336732
NCT07190248
Lead Sponsor
Alliance for Clinical Trials in Oncology
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions